Cellular physical properties in relation to cancer

与癌症相关的细胞物理特性

• 批准号: 6333999
• 负责人: WILLIAM CRAELIUS
• 金额: $ 9.31万
• 依托单位: NIAN-CRAE, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-20 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6333999
• 关键词: angiogenesis inhibitors; biological signal transduction; cardiovascular pharmacology; cell adhesion; cell line; extracellular matrix; flow cytometry; vascular endothelium

Animal tumors shrink when treated with anti-vascular/angiogenic (AVA) drugs, or with genetically modified cellular vectors, that cut-off their blood supplies. Clinical implementation of these promising strategies is impeded however, since the cellular factors that influence AVA are not easily measured. To help predict and monitor the AVA potential of candidate therapies, this project will develop an assay for the expression of cellular physical properties that may be involved in AVA behavior. We will focus initially on vascular-related cells, such as endothelial and other types. Several physical properties expressed by endothelial cells are suspected to influence their angiogenic potential, including: (1) adhesion to matrix; (2) cellular deformability; and (3) mechanotransduction processes. Each of these properties is mediated by specific molecules that may be useful targets of AVA therapy and can be assessed with tools that have been used and/or developed by the PI and collaborators. The proposed project will develop flow cytomechanical assay (FCMA; U.S. patent pending), a novel "front end" to standard flow cytometry, that will measure key physical properties relating to angiogenic and tumorigenic potential. During Phase I we will test the system using various cell lines, in combination with genetic manipulations and AVA drugs provided by researchers and commercial suppliers. Endpoint of the project will be proof of the FCMA concept. PROPOSED COMMERCIAL APPLICATIONS: The end product, FCMA, will be a convenient interface to standard cytometers that will be useful for researchers screening potential anti- angiogenic drugs or genetic vectors, and for clinicians to biopsy specimens. FCMA will also have general applicability to cell cytomechanics relating to several other diseases, including cardiovascular. Thus the potential market for the device is large. Patent protection currently pending will be broadened and strengthened by this project.

当用抗血管/血管生成（AVA）药物或转基因细胞载体治疗（切断血液供应）时，动物肿瘤会缩小。然而，由于影响 AVA 的细胞因素不易测量，这些有希望的策略的临床实施受到阻碍。为了帮助预测和监测候选疗法的 AVA 潜力，该项目将开发一种分析方法，用于检测可能与 AVA 行为有关的细胞物理特性的表达。我们将首先关注血管相关细胞，例如内皮细胞和其他类型。内皮细胞表达的几种物理特性被怀疑影响其血管生成潜力，包括：（1）与基质的粘附； (2)细胞变形能力； (3) 力传导过程。这些特性中的每一个都是由特定分子介导的，这些分子可能是 AVA 治疗的有用靶标，并且可以使用 PI 和合作者已使用和/或开发的工具进行评估。拟议的项目将开发流式细胞力学测定（FCMA；美国专利申请中），这是标准流式细胞术的一种新颖的“前端”，它将测量与血管生成和致瘤潜力相关的关键物理特性。在第一阶段，我们将使用各种细胞系，结合研究人员和商业供应商提供的基因操作和 AVA 药物来测试该系统。该项目的终点将是 FCMA 概念的证明。拟议的商业应用：最终产品 FCMA 将成为标准细胞仪的便捷接口，有助于研究人员筛选潜在的抗血管生成药物或遗传载体，以及临床医生活检标本。 FCMA 还将普遍适用于与其他几种疾病（包括心血管疾病）相关的细胞力学。因此该设备的潜在市场很大。该项目将扩大和加强目前正在申请的专利保护。